MedTrace Logo

Pharmacokinetics of IV Formulation

NCT03076905 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2017-11-01

No results posted yet for this study

Summary

Open label evaluation of a single intravenous dose of F901318 to healthy male and female subjects with pharmacokinetic and safety and tolerability evaluation.

Conditions

  • Invasive Aspergillosis

Interventions

DRUG

F901318

Evaluation of AUC0-t

Sponsors & Collaborators

  • Quotient Clinical

    collaborator OTHER

  • F2G Biotech GmbH

    lead INDUSTRY

Principal Investigators

  • Litza McKenzie, MD · Quotient Clinical

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-31
Primary Completion
2017-07-31
Completion
2017-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03076905 on ClinicalTrials.gov